GAT1 (GABA Transporter 1), encoded by the SLC6A1 gene, is a 12-transmembrane domain protein primarily responsible for the reuptake of gamma-aminobutyric acid (GABA) from the synaptic cleft. As a critical regulator of inhibitory neurotransmission, GAT1/SLC6A1 is a high-value therapeutic target for epilepsy, SLC6A1-related neurodevelopmental disorders, schizophrenia, and neuropathic pain. Developing selective GAT1 modulators requires robust, conformationally intact cellular models and high-specificity validation reagents to overcome the challenges of multi-pass membrane protein assays.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GAT1/SLC6A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Extracellular Loops | SLC6A1 Extracellular Loop Recombinant Proteins Sequence Verified. High Purity (>95%). HEK293 Expressed (Native Glycosylation). Ideal for antibody generation targeting extracellular epitopes. |
View SLC6A1 Products |
| Gene Delivery | SLC6A1 Promise-ORF / Lentivirus Full-length human SLC6A1 ORF for stable cell line construction. Crucial for establishing functional GABA uptake assays. |
View SLC6A1 Products |
| Benchmark Ab | Anti-SLC6A1 Benchmark Antibody Recombinant positive control antibody. Sequence verified for consistent performance in flow cytometry and surface expression validation. |
View SLC6A1 Products |
| Validator | SLC6A1 siRNA Set For target knockdown verification and assay specificity controls. |
View SLC6A1 Products |
| Related Target A | GABRA1 GABA A Receptor Subunit Alpha 1. Primary postsynaptic mediator of GABAergic transmission; essential for evaluating downstream signaling. |
View GABRA1 Products |
| Related Target B | SLC6A11 (GAT3) GABA Transporter 3. Closely related homolog; critical for counter-screening to ensure GAT1-specific selectivity. |
View SLC6A11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 12-TM Protein | Lentivirus-driven stable cell line expression preserves native multi-pass folding and membrane insertion. |
| Homolog Panel Off-Target Screening | Sequence-verified SLC6A11 (GAT3) and SLC6A12 (BGT1) recombinant proteins and cell lines available for selectivity counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and validated small molecule control profiles included |
| False Positives in Knockdown | Sequence-verified siRNA sets included for orthogonal target validation |
Live GAT1/SLC6A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GAT1/SLC6A1 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to gene replacement therapies and antisense oligonucleotides (ASOs). As first-generation small molecules like Tiagabine face limitations due to narrow therapeutic windows and adverse CNS effects, the next wave of R&D is targeting genetic restoration of SLC6A1 expression in haploinsufficiency disorders, as well as highly selective, non-transported blockers to minimize systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Ultragenyx Pharmaceutical, Taysha Gene Therapies | SLC6A1 Epileptic Encephalopathy | Functional Rescue Assays (Need SLC6A1 Lentivirus for stable expression and knock-in validation) |
| Small Molecule Modulators | Neurocrine Biosciences, Cerevel Therapeutics | Epilepsy, Psychiatric Disorders | GABA Uptake Assays (Need sequence-verified cell lines to measure transport kinetics) |
| Antisense Oligonucleotides (ASO) | Stoke Therapeutics, Ionis Pharmaceuticals | Neurodevelopmental Syndromes | Endogenous upregulation validation (Need validated siRNA/shRNA and qPCR primers) |